肝癌患者-话题@MedSci

#肝癌患者#

80篇内容 | 2251人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1969038, encodeId=626f196903879, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Lancet Gastroenterol Hepatol：个体化放疗可显著改善晚期肝癌患者预后, objectType=article, longId=203071, objectId=59472030e150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59472030e150, replyNumber=0, likeNumber=60, createdTime=2021-01-21, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59472030e150, moduleTitle=Lancet Gastroenterol Hepatol：个体化放疗可显著改善晚期肝癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59472030e150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969040, encodeId=f75f19690404b, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Eur Radiol：合并累及血管的肝细胞肝癌患者经姑息TACE治疗效果如何？, objectType=article, longId=205664, objectId=7fb72056643d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fb72056643d, replyNumber=0, likeNumber=106, createdTime=2021-08-27, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fb72056643d, moduleTitle=Eur Radiol：合并累及血管的肝细胞肝癌患者经姑息TACE治疗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fb72056643d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969045, encodeId=4b9b196904563, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, objectType=article, longId=208095, objectId=2339208095d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2339208095d3, replyNumber=0, likeNumber=59, createdTime=2022-01-06, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2339208095d3, moduleTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2339208095d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969037, encodeId=7c72196903ebb, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, objectType=article, longId=202660, objectId=e6f9202660eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f9202660eb, replyNumber=0, likeNumber=64, createdTime=2021-08-02, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f9202660eb, moduleTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6f9202660eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969050, encodeId=53081969050cf, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Lancet子刊 | 我国学者：新型免疫联合治疗大幅延长肝癌患者生存期！, objectType=article, longId=212933, objectId=58b62129339e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58b62129339e, replyNumber=0, likeNumber=60, createdTime=2021-06-24, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b62129339e, moduleTitle=Lancet子刊 | 我国学者：新型免疫联合治疗大幅延长肝癌患者生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b62129339e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969036, encodeId=224c1969036b5, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=全球肝癌患者中，中国人占一半！4种治疗方式，可以提高生存率, objectType=article, longId=201700, objectId=3a54201e0068, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a54201e0068, replyNumber=0, likeNumber=66, createdTime=2021-09-12, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a54201e0068, moduleTitle=全球肝癌患者中，中国人占一半！4种治疗方式，可以提高生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a54201e0068)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969043, encodeId=ad7f196904372, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Hepatol Int：术前即可预测肝癌患者术后6个月内死亡率的个体化模型！, objectType=article, longId=206833, objectId=860c20683363, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=860c20683363, replyNumber=0, likeNumber=82, createdTime=2021-04-24, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=860c20683363, moduleTitle=Hepatol Int：术前即可预测肝癌患者术后6个月内死亡率的个体化模型！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=860c20683363)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969041, encodeId=2d00196904102, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳, objectType=article, longId=205617, objectId=b61a20561e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61a20561e2a, replyNumber=0, likeNumber=87, createdTime=2021-12-26, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61a20561e2a, moduleTitle=罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b61a20561e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969034, encodeId=3675196903402, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=肝胆领域值得期待三大靶点新药介绍，让肝癌患者有更多的选择！, objectType=article, longId=193462, objectId=57141934627d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57141934627d, replyNumber=0, likeNumber=0, createdTime=2020-05-10, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57141934627d, moduleTitle=肝胆领域值得期待三大靶点新药介绍，让肝癌患者有更多的选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57141934627d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969035, encodeId=650e196903551, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率, objectType=article, longId=196693, objectId=dce7196693fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dce7196693fd, replyNumber=0, likeNumber=79, createdTime=2021-02-08, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dce7196693fd, moduleTitle=AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dce7196693fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969030, encodeId=ca94196903063, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=罗氏T+A免疫联合疗法研究获历史性突破，晚期肝癌患者总生存大幅延长, objectType=article, longId=183619, objectId=3a94183619a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a94183619a8, replyNumber=0, likeNumber=91, createdTime=2020-05-31, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a94183619a8, moduleTitle=罗氏T+A免疫联合疗法研究获历史性突破，晚期肝癌患者总生存大幅延长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a94183619a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969031, encodeId=4a741969031f9, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=病例：联合靶向和局部治疗用于Ⅲb期肝癌患者，展现出良好效果, objectType=article, longId=183980, objectId=27ae18398071, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27ae18398071, replyNumber=0, likeNumber=64, createdTime=2020-08-09, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27ae18398071, moduleTitle=病例：联合靶向和局部治疗用于Ⅲb期肝癌患者，展现出良好效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27ae18398071)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969029, encodeId=5ee0196902956, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=病例：TACE+TAI+免疫+靶向，术后肝内多病灶复发肝癌患者疗效竟然达CR, objectType=article, longId=182272, objectId=74991822e285, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74991822e285, replyNumber=0, likeNumber=81, createdTime=2020-06-02, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74991822e285, moduleTitle=病例：TACE+TAI+免疫+靶向，术后肝内多病灶复发肝癌患者疗效竟然达CR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74991822e285)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969028, encodeId=ae9a1969028f0, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Cancer：TACE联合索拉非尼延长晚期肝癌患者寿命, objectType=article, longId=179320, objectId=23901e93204c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23901e93204c, replyNumber=0, likeNumber=71, createdTime=2020-02-14, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23901e93204c, moduleTitle=Cancer：TACE联合索拉非尼延长晚期肝癌患者寿命, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23901e93204c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969032, encodeId=25d119690324b, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性, objectType=article, longId=189092, objectId=e4de1890923b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4de1890923b, replyNumber=0, likeNumber=80, createdTime=2020-12-07, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4de1890923b, moduleTitle=Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4de1890923b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969033, encodeId=7f5519690336c, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Radiology：对于肝癌患者来说CT、MRI均上阵或许能获益更多！, objectType=article, longId=192007, objectId=982e19200eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=982e19200eb9, replyNumber=0, likeNumber=58, createdTime=2020-12-29, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=982e19200eb9, moduleTitle=Radiology：对于肝癌患者来说CT、MRI均上阵或许能获益更多！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=982e19200eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969026, encodeId=2228196902631, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=2019 ASCO丨CheckMate 040再续经典，O+Y首次被证实为晚期肝癌患者带来显著获益, objectType=article, longId=168593, objectId=f6c6168593d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6c6168593d0, replyNumber=0, likeNumber=0, createdTime=2019-09-28, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6c6168593d0, moduleTitle=2019 ASCO丨CheckMate 040再续经典，O+Y首次被证实为晚期肝癌患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6c6168593d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969025, encodeId=413e19690256b, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=2019 ASCO | CheckMate 040再续经典，O+Y首次被证实为晚期肝癌患者带来显著获益, objectType=article, longId=168588, objectId=bbfe1685888c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbfe1685888c, replyNumber=0, likeNumber=96, createdTime=2020-01-05, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbfe1685888c, moduleTitle=2019 ASCO | CheckMate 040再续经典，O+Y首次被证实为晚期肝癌患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbfe1685888c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, objectType=article, longId=165891, objectId=11a416589183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a416589183, replyNumber=0, likeNumber=65, createdTime=2019-11-06, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a416589183, moduleTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11a416589183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969023, encodeId=35af1969023c0, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=免疫治疗不走寻常路，肿瘤进展的肝癌患者依然有生存获益, objectType=article, longId=167061, objectId=ed2816e061a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed2816e061a1, replyNumber=0, likeNumber=62, createdTime=2020-01-21, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed2816e061a1, moduleTitle=免疫治疗不走寻常路，肿瘤进展的肝癌患者依然有生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed2816e061a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肝癌患者

2020-05-29

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Lancet Gastroenterol Hepatol：个体化放疗可显著改善晚期肝癌患者预后

2021-01-21

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Eur Radiol：合并累及血管的肝细胞肝癌患者经姑息TACE治疗效果如何？

2021-08-27

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI

2022-01-06

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者

2021-08-02

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Lancet子刊 | 我国学者：新型免疫联合治疗大幅延长肝癌患者生存期！

2021-06-24

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

全球肝癌患者中，中国人占一半！4种治疗方式，可以提高生存率

2021-09-12

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Hepatol Int：术前即可预测肝癌患者术后6个月内死亡率的个体化模型！

2021-04-24

heli0118 (审核中...)

前往app查看评论内容

#肝癌患者#

罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳

2021-12-26

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

肝胆领域值得期待三大靶点新药介绍，让肝癌患者有更多的选择！

2020-05-10

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率

2021-02-08

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

罗氏T+A免疫联合疗法研究获历史性突破，晚期肝癌患者总生存大幅延长

2020-05-31

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

病例：联合靶向和局部治疗用于Ⅲb期肝癌患者，展现出良好效果

2020-08-09

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

病例：TACE+TAI+免疫+靶向，术后肝内多病灶复发肝癌患者疗效竟然达CR

2020-06-02

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Cancer：TACE联合索拉非尼延长晚期肝癌患者寿命

2020-02-14

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性

2020-12-07

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Radiology：对于肝癌患者来说CT、MRI均上阵或许能获益更多！

2020-12-29

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

2019 ASCO丨CheckMate 040再续经典，O+Y首次被证实为晚期肝癌患者带来显著获益

2019-09-28

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

2019 ASCO | CheckMate 040再续经典，O+Y首次被证实为晚期肝癌患者带来显著获益

2020-01-05

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗

2019-11-06

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

免疫治疗不走寻常路，肿瘤进展的肝癌患者依然有生存获益

2020-01-21

科室
- - 订阅+
  - 更多科室
工具
服务